Open Collections

UBC Faculty Research and Publications

Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD Leitao Filho, Fernando S.; Ra, Seung W; Mattman, Andre; Schellenberg, Robert; Criner, Gerard J.; Woodruff, Prescott G.; Lazarus, Stephen C.; Albert, Richard; Connett, John E.; Han, Meilan K.; Martinez, Fernando J.; Leung, Janice M.; Man, S. F. P.; Aaron, Shawn D.; Reed, Robert M.; Sin, Don D.

Abstract

Background: The literature is scarce regarding the prevalence and clinical impact of IgG subclass deficiency in COPD. We investigated the prevalence of IgG subclass deficiencies and their association with exacerbations and hospitalizations using subjects from two COPD cohorts. Methods: We measured IgG subclass levels using immunonephelometry in serum samples from participants enrolled in two previous COPD trials: Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO; n = 976) and Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE; n = 653). All samples were collected from clinically stable participants upon entry into both studies. IgG subclass deficiency was diagnosed when IgG subclass levels were below their respective lower limit of normal: IgG1 

Item Metadata

Title
Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD
Creator
Leitao Filho, Fernando S.; Ra, Seung W; Mattman, Andre; Schellenberg, Robert; Criner, Gerard J.; Woodruff, Prescott G.; Lazarus, Stephen C.; Albert, Richard; Connett, John E.; Han, Meilan K.; Martinez, Fernando J.; Leung, Janice M.; Man, S. F. P.; Aaron, Shawn D.; Reed, Robert M.; Sin, Don D.
Contributor
University of British Columbia. Centre for Heart Lung Innovation; St. Paul's Hospital (Vancouver, B.C.)
Publisher
BioMed Central
Date Issued
2018-02-14
Description
Background: The literature is scarce regarding the prevalence and clinical impact of IgG subclass deficiency in COPD. We investigated the prevalence of IgG subclass deficiencies and their association with exacerbations and hospitalizations using subjects from two COPD cohorts. Methods: We measured IgG subclass levels using immunonephelometry in serum samples from participants enrolled in two previous COPD trials: Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO; n = 976) and Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE; n = 653). All samples were collected from clinically stable participants upon entry into both studies. IgG subclass deficiency was diagnosed when IgG subclass levels were below their respective lower limit of normal: IgG1 
Subject
IgG; IgG subclass deficiency; COPD; Exacerbation; Hospitalization
Genre
Article
Type
Text
Language
eng
Date Available
2018-02-14
Provider
Vancouver : University of British Columbia Library
Rights
Attribution 4.0 International (CC BY 4.0)
DOI
10.14288/1.0363887
URI
http://hdl.handle.net/2429/64641
Affiliation
Medicine, Faculty of; Other UBC; Non UBC; Medicine, Department of; Pathology and Laboratory Medicine, Department of
Citation
Respiratory Research. 2018 Feb 14;19(1):30
Publisher DOI
10.1186/s12931-018-0733-z
Peer Review Status
Reviewed
Scholarly Level
Faculty
Copyright Holder
The Author(s).
Rights URI
http://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution 4.0 International (CC BY 4.0)